Dr. Ai on Potential With Mogamulizumab in CTCL
3 Visualizzazioni
• 08/09/23
0
0
Incorporare
administrator
Iscritti
Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell lymphoma
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti